NEXT Life Sciences Completes 40-Man Phase 2 Trial for 10-Year Male Contraceptive

1 articles · Updated · The Washington Post · Sep 30

NEXT Life Sciences said its Phase 2 trial placed Plan A successfully in the vas deferens of 40 men and reduced sperm counts to zero, with the company reporting strong safety and efficacy.
Plan A uses a nonhormonal hydrogel called Vasalgel to block sperm for about 10 years; NEXT is now testing reversal with a sodium bicarbonate injection and plans to start Phase 3 soon.
The company is targeting FDA approval in 2028 and says demand is building, citing 55,000 men on its interest list and one promotional video that drew 4.5 million views overnight.
The advance comes as U.S. developers race to expand male birth-control options beyond condoms and vasectomy, while rival Contraline prepares a larger study of its ADAM hydrogel after early proof-of-concept work.

Sources

Can hydrogel male birth control finally deliver a safe, truly reversible alternative to condoms and vasectomy after decades of delays?

If Plan A and ADAM work, what matters more for male contraception: the science, or cost, access, and trust?

Why did RISUG stall for years in India while U.S. versions now appear closer to market?

1 total